2000 Alameda de las Pulgas, suite 120
About Innovent Biologics
Innovent Biologics (USA), Inc. is the US headquarters of one of the largest and well-known biotechnology companies based in China focused on developing innovative therapeutics in oncology, autoimmune, metabolic and other major diseases. We have a small start-up team environment situated within a ~$11 billion dollar Market Cap parent company with almost 3000 employees.
Established in 2011, Innovent has developed a fully-integrated platform which includes research & development, manufacturing, clinical development, and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 23 innovative assets in the fields of oncology, autoimmune, metabolic diseases and other major therapeutic areas, with sixteen in clinical development, five in Phase 3 clinical trials, and will have 3 biologics approved this year, plus a PD-1 inhibitor, Tyvyt®, officially approved for marketing in China late 2018.
On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong. The company has strategic collaborations with Eli Lilly and Company, Adimab, Incyte, Hanmi, Coherus, Alector, and other international pharmaceutical companies. For more information, please visit: www.innoventbio.com.
3 articles with Innovent Biologics
Innovent Announces NMPA Granted New Indication Approval for SULINNO® (Adalimumab Injection) in China for the Treatment of Polyarticular Juvenile Idiopathic Arthritis
Innovent Biologics, Inc. announced that SULINNO®, a recombinant human anti-TNF-α monoclonal antibody drug, has been officially approved by the National Medical Products Administration of China for the treatment of polyarticular juvenile idiopathic arthritis, which is the fourth approved indication of SULINNO® in China.
Innovent Releases Phase 3 Results of TYVYT® (Sintilimab Injection) in Combination with BYVASDA® (Bevacizumab Biosimilar Injection) as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma at ESMO ASIA Virtual Congress 2020
Innovent Biologics, Inc. announced that the results of the Phase 3 ORIENT-32 study were released in a late-breaking proffered oral presentation at the European Society of Medical Oncology Asia Virtual Congress 2020.
Innovent Announces the Results of the Phase I Clinical Trial of IBI302, a First-in-class Ophthalmic Recombinant Human Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Related Macular Degeneration at 2020 AAO
Innovent Biologics, Inc. announces that the results of the Phase I clinical trial of IBI302, a first-in-class ophthalmic recombinant human anti-VEGF and anti-complement bi-specific fusion protein for neovascular age-related macular degeneration is released in e-poster at 2020 American Academy of Ophthalmology.